The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation

PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when bortezomib was used to treat refractory AMR. MATERIALS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Juhan, Kim, Beom Seok, Park, Yongjung, Lee, Jae Geun, Lim, Beom Jin, Jeong, Hyeon Joo, Kim, Yu Seun, Huh, Kyu Ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630054/
https://www.ncbi.nlm.nih.gov/pubmed/26446648
http://dx.doi.org/10.3349/ymj.2015.56.6.1638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630054/
https://www.ncbi.nlm.nih.gov/pubmed/26446648
http://dx.doi.org/10.3349/ymj.2015.56.6.1638

Ejemplares similares